Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study

Christiane Querfeld, John A. Thompson, Matthew H. Taylor, Jennifer DeSimone, Jasmine Zain, Andrei R. Shustov, Carolyn Johns, Sue McCann, Gloria H. Y. Lin, Penka S. Petrova, Robert A. Uger, Naomi Molloy, Yaping Shou, Oleg E. Akilov